Fritextsökning
Artiklar per år
Innehållstyper
-
“We aim to be a start-up company with an academic spirit”
Chronic pain and Alzheimer’s are two diseases that plague many people worldwide and seem impossible to cure. However, Huddinge-based company Alzecure is working on developing drugs for both conditions.
-
Biosimilars bring price pressure, but are they sufficiently used?
When biosimilars were introduced just over 16 years ago, hopes were raised that they would give many more patients access to effective but otherwise extremely expensive treatments with biological drugs. So, how well has Swedish healthcare used biosimilars? The answer partly depends on whom you ask.
-
Bought a tablet factory – and built his own empire
In 1995, Thomas Eldered was CEO of one of Pharmacia’s factories in the Stockholm area when the Swedish pharmaceutical giant, after a takeover, decided to move its production abroad. 34-year-old Thomas was facing an imminent risk of losing his job. However, instead, it actually turned out to be the starting point for one of the biggest success stories in Swedish life science.
-
Anders Blanck about his 17 years at Lif: “The industry is enjoying greater public trust now"
The announcement came as a surprise to those around him, but according to the protagonist himself, the timing was excellent. Anders Blanck is now leaving Lif – a decision that has been growing for some time. “I have been pretty much married to my mission. However, I will turn 56 this autumn, and if I’m going to do something else in my professional life, now is the time,” he says.
-
Amorphous materials take centre stage when Orexo develops new formulations
Swift resolution but with maintained stability. Orexo’s new drug delivery platform tackles the problem of amorphous materials. “Our technology has the positive properties of the material, and it also cracks some of the problems,” says the company’s Research and Development Manager Robert Rönn.
-
BioVentureHub CEO: “Companies with a high degree of interaction achieve greater success”
For the first time since its inception, AstraZeneca’s BioVentureHub can now recruit new companies, as some of its tenants have grown significantly and are leaving the hub. This is the message from the biohub’s CEO Magnus Björsne in an interview, in which he also highlights a study that points out that companies with a high degree of interaction with other companies achieve greater success.
-
Ny metod för mikroskopi öppnar genväg till nya läkemedel
Forskare vid Chalmers har utvecklat en helt ny mikroskopiteknik för att kunna studera de minsta biologiska partiklarna i sitt naturliga tillstånd – och därmed öppna vägar för snabbare utveckling av nya läkemedel och vaccin.
-
A growing industry in Denmark: “One new life science company a week”
The life science sector in eastern Denmark continues to grow in the number of employees, as well as the number of companies. An emerging problem is the shortage of labour, a new report reveals.
-
Växande bransch i Danmark – "Ett nytt life science-företag i veckan"
Life science-sektorn i östra Danmark fortsätter att växa, både i antal anställda och antal företag. Ett uppseglande problem är bristen på arbetskraft, enligt en ny rapport.
-
Anna Törner: To kill your darlings
Hopes were high when Anna Törner and her colleague started a study on a dietary supplement that seemed unbelievably good. “Enthusiastically, we dreamed of exciting results and perhaps a publication in a high-impact journal,” she writes in a column.
-
Hello Angelica Loskog!
Life Science Sweden would like to know more about Angelica Loskog and interviews her about her life as a researcher.
-
We will now publish more news in English – and offer yet another newsletter
Starting next week, Life Science Sweden will begin offering a newsletter entirely in English.
-
Petter Hartman: Hög tid att höja prioriteten för säkerhetsfrågorna
Är svensk life science rustad för att möta ett förhöjt intresse från främmande makt med industrispionage och cyberattacker som följd? Och går det ens att skydda sig när svaren på våra hälsoutmaningar kräver öppenhet och internationellt samarbete? Svaret är ja, men det är hög tid för bolag och forskningsinstitutioner att ge säkerhetsfrågorna högre prioritet, skriver Petter Hartman i en krönika.
-
Miljonstöd till 14 life science-projekt för bättre hälsa
Nya tekniker för fixering av handfrakturer, AI-prediktion av blodtrycksfall och tidig detektion av bukspottkörtelcancer finns bland de 14 projekt för bättre hälsa som får miljonstöd av innovationsprogrammen Swelife och Medtech4health.
-
This is how Anette Steenberg will put Medicon Valley on the world map
Anette Steenberg has been CEO of the Swedish-Danish life science cluster Medicon Valley Alliance since 1 November last year. Life Science Sweden called her to ask about her visions and the challenges of merging the worlds of Swedish and Danish life science.
-
CAR-T therapies give continued hope: “Almost half of the patients have become disease-free”
become disease-free, at least of those treated with Yescarta, which are the ones I know best,” says Gunilla Enblad, Chairman of the national working group for CAR-T treatment.
-
“Together Stockholm-Uppsala and Medicon Valley can make Scandinavia a leading life science region”
“Denmark, Sweden, Norway and Finland all have national life science strategies, but the Swedish strategy is the only one explicitly emphasizing the Nordic dimension. But what if the leading life science nations, Denmark and Sweden, joined forces, took the lead and pioneered Nordic life science collaboration? Wouldn´t we then be able to "bake a bigger cake?", writes Anette Steenberg and Ulf G. Andersson in a debate article.
-
VD:n om att bygga världsföretag: ”Utveckla inte läkemedel för Nobelpris”
För att bygga ett medicinskt företag i världsklass krävs fyra grundelement, enligt Ascelia Pharmas vd Magnus Corfitzen. – Tre av dem blir ni inte överraskade av. Den fjärde, I don´t know, sa han när han talade på The Future of Swedish & Danish Life Science.
-
Sweden and Denmark – this is how they choose their strategies
Scandinavia’s two major powers in pharmaceutical research have developed strategies for growth in life science, and both countries aim to become world leaders.
-
Grundare och känd forskare lämnar Alligator Bioscience
Alligator Bioscience grundare Carl Borrebaeck lämnar bolaget i protest mot valberedningens förslag på ny styrelse. ”Företaget dräneras på immunonkologisk kompetens”, säger han.
-
Marie Gårdmark: Big data evidence generation drives change in the EU regulatory system
Rapid developments in technology have led to the possibility for the generation and analysis of vast volumes of data. Will the availability of big data lead to fundamental changes to the regulatory system? In a column Marie Gårdmark, CEO and Senior Consultant at RegSmart Life Science, develops her views on this subject.
-
Column: Why there cannot be a complete cure for cancer – but there is certainly another way!
"Is there a new way we need to be thinking about how to prevent cancer?" Lucy Robertshaw reflects upon which is the smartest way to beat cancer.
-
Björn Arvidsson: Let's build on the positive momentum
Progress needs narratives and heroes, and more than ever, going into the new year feels like an opportunity for a fresh start.
-
Lucy Robertshaw: There is a bio revolution happening right now
Lucy Robertshaw is both proud and excited to be taking the baton of moderating this year’s Pharma Outsourcing event.
BREAKING